OVID — Ovid Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $219.51m
- $113.68m
- $0.39m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 76.7 | 72 | 188 | 129 | 106 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1.13 | 0.142 | 0 | — | — |
Prepaid Expenses | |||||
Total Current Assets | 79.8 | 74.8 | 190 | 131 | 110 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.068 | 0.136 | 0.243 | 16.1 | 14.7 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 80.8 | 75.9 | 195 | 155 | 144 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 10.5 | 22.1 | 14.8 | 6.99 | 11.5 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 10.8 | 32.3 | 14.8 | 23 | 56.2 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 70 | 43.6 | 180 | 132 | 87.8 |
Total Liabilities & Shareholders' Equity | 80.8 | 75.9 | 195 | 155 | 144 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |